Piper Jaffray Companies reiterated their overweight rating on shares of Oxford Immunotec Global (NASDAQ:OXFD) in a research note released on Sunday morning, The Fly reports.

OXFD has been the subject of several other research reports. ValuEngine raised shares of Oxford Immunotec Global from a hold rating to a buy rating in a research note on Wednesday, September 12th. BidaskClub raised shares of Oxford Immunotec Global from a sell rating to a hold rating in a research note on Thursday, October 18th. Finally, Zacks Investment Research raised shares of Oxford Immunotec Global from a hold rating to a buy rating and set a $16.00 price target for the company in a research note on Friday, August 3rd. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Oxford Immunotec Global presently has an average rating of Buy and a consensus price target of $16.67.

OXFD stock opened at $15.24 on Friday. The firm has a market cap of $410.55 million, a PE ratio of -11.21 and a beta of -0.09. Oxford Immunotec Global has a 52-week low of $10.00 and a 52-week high of $19.19. The company has a quick ratio of 4.86, a current ratio of 5.39 and a debt-to-equity ratio of 0.41.

Oxford Immunotec Global (NASDAQ:OXFD) last released its quarterly earnings results on Friday, November 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.14). The business had revenue of $16.10 million for the quarter, compared to the consensus estimate of $33.60 million. Oxford Immunotec Global had a negative net margin of 12.51% and a negative return on equity of 40.10%. Oxford Immunotec Global’s revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.70) EPS. On average, research analysts predict that Oxford Immunotec Global will post -0.97 EPS for the current year.

In related news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $15.50, for a total transaction of $46,500.00. Following the completion of the transaction, the director now owns 9,000 shares of the company’s stock, valued at $139,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Peter Wrighton-Smith sold 86,100 shares of Oxford Immunotec Global stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $18.42, for a total transaction of $1,585,962.00. Following the transaction, the chief executive officer now directly owns 539,569 shares of the company’s stock, valued at approximately $9,938,860.98. The disclosure for this sale can be found here. Insiders have sold 149,100 shares of company stock valued at $2,564,662 in the last ninety days. Insiders own 6.61% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its stake in Oxford Immunotec Global by 11.2% during the third quarter. Wells Fargo & Company MN now owns 45,820 shares of the company’s stock worth $744,000 after buying an additional 4,605 shares during the last quarter. Citadel Advisors LLC raised its stake in Oxford Immunotec Global by 6.2% during the third quarter. Citadel Advisors LLC now owns 84,689 shares of the company’s stock worth $1,375,000 after buying an additional 4,911 shares during the last quarter. Northern Trust Corp raised its stake in Oxford Immunotec Global by 3.1% during the second quarter. Northern Trust Corp now owns 265,487 shares of the company’s stock worth $3,423,000 after buying an additional 7,862 shares during the last quarter. Renaissance Technologies LLC raised its stake in Oxford Immunotec Global by 84.7% during the second quarter. Renaissance Technologies LLC now owns 21,058 shares of the company’s stock worth $271,000 after buying an additional 9,658 shares during the last quarter. Finally, Bank of Montreal Can bought a new position in Oxford Immunotec Global during the second quarter worth $132,000. 92.24% of the stock is owned by institutional investors and hedge funds.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Recommended Story: What is a Tariff?

The Fly

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.